The New York Times / Wall Street Journal / The New York Times Company / Dow Jones & Company Inc. / Thomson Reuters / Reuters / /
Country
United States / /
Currency
USD / /
Facility
DanaFarber Cancer Institute / /
IndustryTerm
advisory / supply chain / redundant manufacturing locations / insurance plan / import product / case management services / pharmaceutical supply chain / pharmaceutical agents / manufacturing practice / active pharmaceutical ingredients / /
MedicalCondition
serious diseases / cancer / epidemic / U.S. cancer / endometrial cancer / common and treatable cancers / diseases / /
MedicalTreatment
chemotherapy / /
Organization
United States Senate / American Society of Health-System Pharmacists / U.S. FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH / Advocate Foundation / U.S. Food and Drug Administration / DEA / U.S. Senate Health / Education / Labor & Pensions Committee / FDA Center for Drug Evaluation and Research / Committee on Health / Education / Labor and Pensions / National Patient Advocate Foundation / FDA / Federal Trade Commission / American Society of Clinical Oncology / DanaFarber Cancer Institute in Boston / Medicare / /
Person
Robert Mayer / Ezekiel Emanuel / /
Position
president / Physician / NANCY DAVENPORT-ENNIS FOUNDER AND CHIEF EXECUTIVE OFFICER / /
Product
Cisplatin / Cytarabine / Doxil / /
PublishedMedium
the Wall Street Journal / The New York Times / the Agency review / /
STATEMENT OF NANCY DAVENPORT-ENNIS FOUNDER AND CHIEF EXECUTIVE OFFICER NATIONAL PATIENT ADVOCATE FOUNDATION